eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes.
Lei GaoFrancisco J RamirezJody Tori O CabreraMathews V VargheseMakiko WatanabeAtsumi Tsuji-HosokawaQiuyu ZhengMingya YangMd Rahatullah RazanCarrie L KempfSara M CampJian WangJoe G N GarciaAyako MakinoPublished in: Diabetologia (2024)
These data indicate that increased i/eNAMPT expression contributes to the development of diabetic coronary microvascular dysfunction, and provide compelling support for eNAMPT inhibition as a novel and effective therapeutic strategy for CMD in diabetes.
Keyphrases
- type diabetes
- coronary artery disease
- coronary artery
- glycemic control
- cardiovascular disease
- poor prognosis
- climate change
- electronic health record
- insulin resistance
- oxidative stress
- aortic stenosis
- big data
- binding protein
- machine learning
- artificial intelligence
- data analysis
- left ventricular
- atrial fibrillation